SITC 27th Annual Meeting Presentations

October 26-28, 2012
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD

Presentations are posted online based upon presenter approval.

Program Schedule

Friday, October 26

7:50 am - 8:00 am President's Welcome
Thomas F. Gajewski, MD, PhD - University of Chicago
8:00 am - 8:45 am Richard V. Smalley, MD Memorial Lectureship PDF
Theresa L. Whiteside, PhD - University of Pittsburgh Cancer Institute
  Plenary Session 301: T Cell Modulating Strategies
Co-chairs:
Nicholas P. Restifo, MD - National Cancer Institute
Cassian Yee, MD - Fred Hutchinson Cancer Research Center
8:45 am - 9:15 am Curative Cancer Immunotherapy Using Stem Cell-like T Cells
Nicholas P. Restifo, MD - National Cancer Institute
9:15 am - 9:45 am Adoptive T Cell Therapy: Faster, Higher, Stronger PDF
Cassian Yee, MD - Fred Hutchinson Cancer Research Center
10:15 am - 10:45 am Profound Negative Regulation of T Cell Immunity by Nk Cells
Pamela S. Ohashi, PhD - Ontario Cancer Institute/University Health Network
10:45 am - 11:00am Memory CD8+ T Cells Induce Precocious Effector Differentiation of Naïve CD8+ T Cells in a Fasl-Fas Dependent Manner: a New Mode of T-T Lymphocyte Interaction and Cross Talk PDF
Christopher A. Klebanoff, MD - National Institutes of Health
11:00 am - 11:15 am Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy
Bryan A. Irving, PhD - Genentech, Inc.
11:15 am - 11:30 am Blockade of PD-L1 Mediated Immunosupression for Cancer Therapy - MEDI4736, Monoclonal Antibody Discovery and Preclinical Development
Ross A. Stewart, PhD - MedImmune
  Plenary Session 302: Late-Breaking Oral Abstracts
11:30 am - 11:45 am A Phase II Study with the Anti-CTLA-4 mAb Tremelimumab in Advanced Malignant Mesothelioma: MESOTTREM-2008
Luana Calabró, MD - University Hospital of Siena
11:45 am - 12:00 pm Treatment of Non-Hodgkin Lymphoma with CAR-Transduced CD19-Specific Central Memory Derived T Cells PDF
Stephen J. Forman, MD - City of Hope
12:00 pm - 1:30 pm Poster Viewing and Presentations
  Concurrent Session 304: DC Subsets / Cancer Vaccines
Co-chairs:
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
Cornelis J.M. Melief, MD, PhD - Leiden University Medical Center
1:30 pm - 1:55 pm Promoting the Effectiveness of Synthetic Cancer Vaccines PDF
Cornelis J.M. Melief, MD, PhD - Leiden University Medical Center
1:55 pm - 2:08 pm Preoperative Sipuleucel-T Results in Tumor Lymphocyte Infiltration in Prostate Cancer Specimens: Evidence of Immune Activation and Response Within the Prostate Tumor Microenvironment
Lawrence Fong, MD - University of California, San Francisco
2:08 pm - 2:21 pm A Novel Dendritic Cell-based Vaccine for Her-2-Positive Early Breast Cancer PDF
Brian Czerniecki, MD, PhD - University of Pennsylvania
2:21 pm - 2:34 pm Randomized Trial of Two Active-Specific Immunotherapy Products Derived From Autologous, Proliferating, Self-renewing Tumor Cells in Patients with Metastatic Melanoma
Robert O. Dillman, MD, FACP - Hoag Cancer Center
2:34 pm - 3:00 pm Optimization of DC-based Cancer Therapies PDF
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
1:30 pm - 3:00 pm Concurrent Session 305: Targeting Immune Suppression
Co-chairs:
Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre
David H. Munn, MD - Georgia Health Sciences University
1:30 pm - 2:00 pm IDO and Immune Suppression PDF
David H. Munn, MD - Georgia Health Sciences University
2:00 pm - 2:15 pm Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy with Cetuximab and Correlated with Clinical Outcome
Hyun-Bae Jie, PhD - University of Pittsburgh
2:15 pm - 2:30 pm mir-124 as a Novel Immunotherapeutic Molecule to Reverse Gliomamediated Immune Suppression and Enhance Anti-Tumor Clearance
Amy B. Heimberger, MD - University of Texas MD Anderson Cancer Center
2:30 pm - 3:00 pm The Tumor Microenvironment Can Vary with Anatomical Site to Affect Responses to Therapy PDF
Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre
  Plenary Session 306: Immunity of Oncolytic Viruses
Co-chairs:
Howard L. Kaufman, MD, FACS - Rush University Medical Center
Aladar A. Szalay, PhD - Genelux Corporation
3:15 pm - 3:45 pm Tropism of Oncolytic Vaccinia Virus Constructs for Human
Mononuclear Cell Subsets
PDF

Boris Minev, MD - Genelux Corporation
3:45 pm - 4:15 pm Oncolytic Virotherapy as Cancer Immunotherapy PDF
Richard Vile, PhD - Mayo Clinic
4:15 pm - 4:45 pm Modulating the Tumor Microenvironment to Enhance Antitumor Immunity in Preclinical and Clinical Settings: Antigen Encoding Poxvirus Vectors Overcome Immune Escape PDF
Edmund C. Lattime, PhD - The Cancer Institute of New Jersey
4:45 pm - 5:00 pm Effect of HCV Viraemia on NK Cells
Maria Libera Ascierto, PhD - National Institutes of Health
5:00 pm - 5:15 pm Combination Therapy of Intratumoral CRT/E7 Vaccinia Virus and Cisplatin Treatment Enhance the Antigen-Specific T Cell Immune Responses and Therapeutic Antitumor Effects
Sung Yong Lee, MD, PhD - Johns Hopkins Medical Institutions
5:15 pm - 5:30 pm Cancer Immunotherapy Guidelines (CIG) Update
Howard L. Kaufman, MD, FACS - Rush University Medical Center
5:30 pm - 5:45 pm US Food and Drug Administration (FDA) Update PDF
Raj K. Puri, MD, PhD - US Food and Drug Administration, CBER
5:45 pm - 6:00 pm National Cancer Institute (NCI) Update PDF
William Merritt, PhD - National Cancer Institute
6:00 pm - 6:30 pm SITC Membership Business Meeting
6:30 pm - 8:00 pm Poster and Networking Reception
8:00 pm - 10:00 pm Early Career Scientists Evening Networking Event


Saturday, October 27

7:00 am - 7:45 am Early Career Scientists "Meet-the-Expert" Breakfast
8:00 am - 8:45 am Keynote Address:
Using Genomics To Understand Cancer Immunoediting And Guide Immunotherapy PDF
Robert D. Schreiber, PhD - Washington University St. Louis
  Plenary Session 401: Combining Immunotherapy and Other Therapies
Co-chairs:
Antoni Ribas, MD - UCLA Medical Center
Laurence Zitvogel, MD, PhD - Institute Gustave Roussy
8:45 am - 9:15 am Combining Immunotherapy and Targeted Therapy for Melanoma PDF
Antoni Ribas, MD - UCLA Medical Center
9:15 am - 9:30 am PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma PDF
Bryon D. Johnson, PhD - Medical College of Wisconsin
9:30 am - 9:45 am Pharmacokinetics and Immunological Effects of Human Il-15/Il-15Ra Heterodimeric Complexes in Mice and Macaques
Cristina Bergamaschi, PhD - Frederick National Laboratory for Cancer Research
9:45 am - 10:00 am ADXS11-001 Lm-LLO Immunotherapy Targeting HPV-E7: Preliminary Safety and Survival Data From A Phase 2 Study in Indian Women With Recurrent/Refractory Cervical Cancer PDF
Robert Petit, PhD - Advaxis
10:30 am - 11:00 am Immunomodulation and Tyrosine Kinase Inhibition
Ronald DeMatteo, MD, FACS - Memorial Sloan-Kettering Cancer Center
11:00 am - 11:30 am Imatinib Mesylate: An Efficient Cancer Immunotherapy
Laurence Zitvogel, MD, PhD - Institute Gustave Roussy
  Plenary Session 402: Critical Issues in Immunotherapy Clinical Trials
Co-chairs:
Samir N. Khleif, MD - Georgia Health Sciences
Howard Streicher, MD - National Institutes of Health
11:30 am - 11:45 am The Projection of Immunotherapy Clinical Design of the 21st Century
Howard Streicher, MD - National Institutes of Health
11:45 am - 12:00 pm Critical Issues for Early Trial Design in Immunotherapy PDF
Osama Rahma, MD - National Cancer Institute
12:00 pm - 12:15 pm Design Issues in the Immunotherapy Combinatorial Trials PDF
Antoni Ribas, MD - UCLA Medical Center
  Plenary Session 403: Late-Breaking Oral Abstract
Chair: Francesco Marincola, MD - National Institutes of Health
12:30 pm - 12:45 pm 12-Chemokine Gene Signature Identifies Lymph Node-Like Structures In Melanoma: Potential For Patient Selection For Immunotherapy?
Jim Mulè, PhD - H. Lee Moffitt Cancer Center & Research Institute
12:45 pm - 2:00 pm Poster Viewing and Presentations
  Concurrent Session 404: T Cell Manufacture and Potency Testing
Co-chairs:
Daniel J. Powell, Jr., PhD - University of Pennsylvania
David F. Stroncek, MD - National Institutes of Health
2:00 pm - 2:30 pm TIL Adoptive Cell Therapy for Melanoma: Trials and Tribulations in the Quest for FDA Approval PDF
Laszlo G. Radvanyi, PhD - MD Anderson Cancer Center
2:30 pm - 3:00 pm Developing Commercially Relevant T Cell Therapy Manufacturing Processes PDF
Robert Keefe, PhD - Lonza Walkersville, Inc.
3:00 pm - 3:30 pm Artificial Antigen Presenting Cells as a Standardized Platform for TIL Expansion PDF
Daniel J. Powell, Jr., PhD - University of Pennsylvania
  Concurrent Session 405: Single Cell High Throughput Technologies Immune Monitoring
Co-chairs:
Alessandra Cesano, MD, PhD - Nodality
Begonya Comin-Anduix, PhD - UCLA School of Medicine
2:00 pm - 2:30 pm A Single Cell Network Profiling (SCNP) View of the Immune System PDF
Alessandra Cesano, MD, PhD - Nodality, Inc.
2:30 pm - 2:45 pm Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma PDF
Pia Kvistborg, MD - Netherlands Cancer Institute
2:45 pm - 3:00 pm High-Throughput Identification of Biomarkers of Longevity in Ipilimumab-Treated Melanoma Patients Using Polychromatic Flow Cytometry
Janet C. Siebert, MS - CytoAnalytics
3:00 pm - 3:30 pm A Shape for Cancer and Immunity at the Single Cell Level PDF
Garry P. Nolan, PhD - Stanford School of Medicine
4:00 pm - 5:20 pm Plenary Session 406: Presidential Abstract Session
Chair:
Thomas F. Gajewski, MD, PhD - University of Chicago
4:00 pm - 4:20 pm Forcing NF-sB in T Cells Promotes Tumor Rejection
Cesar Evaristo, PhD - University of Chicago
4:20 pm - 4:40 pm CARs For Childhood Cancer: Development and Comparison of Permanently and Transiently-Modified T-cells Targeting All and Neuroblastoma PDF
Nathan Singh - University of Pennsylvania
4:40 pm - 5:00 pm Inhibition of Glycolytic Flux Enhances CD8+ T Cell Memory, Stemness and Anti-Tumor Function
Madhusudhanan Sukumar, PhD - National Cancer Institute
5:00 pm - 5:20 pm Tgfß is a Master Regulator of the Pro-immunogenic Effects of Radiotherapy
Claire Vanpouille-Box, PhD - NYU School of Medicine
  Cancer Immunotherapy Trials Network (CITN) Update
5:20 pm - 5:30 pm Martin A. “Mac” Cheever, MD - CITN Principal Investigator, Fred Hutchinson Cancer Research Center
5:30 pm - 5:35 pm IL15 Trial
Jeffrey S. Miller, MD - University of Minnesota Cancer Center
5:35 pm - 5:40 pm IL7 Trial
Lawrence Fong, MD - University of California, San Francisco
5:40 pm - 5:45 pm IDO Inhibitor Trial (Melanoma)
Craig L. Slingluff, Jr., MD - University of Virginia
5:45 pm - 5:50 pm IDO Inhibitor Trial (Ovarian Cancer)
Kunle Odunsi, MD, PhD - Roswell Park Cancer Institute
5:50 pm - 6:15 pm Awards Ceremony
6:15 pm - 8:00 pm Presidential Reception with Poster Viewing
8:00 pm The Checkpoints Performance


Sunday, October 28

  Plenary Session 500: Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
Co-chairs:
Philip D. Greenberg, MD - University of Washington
Steven A. Rosenberg, MD, PhD - National Cancer Institute
8:00 am - 8:30 am Adoptive Immunotherapy of Cancer PDF
Steven A. Rosenberg, MD, PhD - National Cancer Institute
8:30 am - 9:00 am Building a Better T Cell for Targeting Tumors PDF
Philip D. Greenberg, MD - University of Washington
9:00 am - 9:30 am Targeting CD19 in Adult and Pediatric Leukemia
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
9:30 am - 9:45 am Adoptive T Cell Therapy with a TCR Engineered for Nanomolar Affinity Shows Improved Anti-Tumor Efficacy Compared to the Micromolar Wildtype TCR
Carolina M. Soto - University of Illinois
9:45 am - 10:00 am Selection of PD-1, LAG-3, TIM-3 and 41BB positive CD8 T Cells in the Fresh Tumor Digest Enriches for Melanoma-Reactive Cells
Alena Gros, PhD - National Cancer Institute
10:00 am - 10:15 am Role of the PD-1/PD-L1 Pathway on Regulatory T Cell Development, Induction and Iunction in Vivo
Justin P. Kline, MD - University of Chicago
10:15 am Annual Meeting Adjourns
10:30 am - 12:00 pm Hot Topic Symposium

 

Creative Commons License

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

  • Go to SITC’s YouTube channel to hear Annual Meeting Organizers talk about highlights of the meeting!
  • October 24, 2012
    SITC Early Career Scientists Professional Development Session
  • October 24-25, 2012
    SITC Workshop – Focus on the Target: The Tumor Microenvironment
  • October 25, 2012
    SITC Primer on Tumor Immunology and Cancer Immunotherapy™
  • October 26-28, 2012
    SITC 27th Annual Meeting
  • October 28, 2012
    SITC Hot Topic Symposium: PD-1/PD-L1: Right on Target
     

SITC has opportunities and solutions available no matter what your goal!

SITC offers General, Marketing and Educational support opportunities for the Society as well as for all SITC educational programs.

Platinum

Silver

EMD Serono
Prometheus

Bronze

Amgen
Celgene
Dendreon
Otsuka